Japanese company Eisai has entered an exclusive global licensing agreement with CORE Biomedicine for several preclinical oncology programmes. The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates. CORE Biomedicine plans to use these assets to support its precision medicine strategy and aims to develop therapies for a broader set of cancer patients. CORE Biomedicine co-founder and business development head Dr Douglas McMillin said: “CORE was created to advance an exceptional portfolio of oncology programmes grounded in deep cancer biology, precision medicine and lineage therapeutics. Additionally, the company’s wholly owned subsidiary, CORE Biomedicine Japan, received a grant through the Strengthening Program for Pharmaceutical Startup Ecosystem, a scheme run by the Japan Agency for Medical Research and Development (AMED).